Recent News

• 02.06.2025 - Guggenheim Securities SMID Cap Biotech Conference
• 01.30.2025 - Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
• 01.23.2025 - Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
• 01.08.2025 - Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
• 12.03.2024 - Sarah Schram (William Blair)
• 12.03.2024 - Evercore HealthCONx Conference

Recent Filings

• 01.23.2025 - 8-K Current report
• 01.23.2025 - EX-99.1 EX-99.1
• 12.19.2024 - 4 Statement of changes in beneficial ownership of securities